Icon reports Q4 adjusted EPS $3.46, consensus $3.45

Reports Q4 revenue $2.07B, consensus $2.09B. Reports closing backlog of $22.8B, an increase of 2.4% on Q3. The company said, “With our focus on delivering innovative clinical development solutions, ICON’s solid performance in quarter four and the full year 2023 reflects continued market leadership across the customer segments we serve. Our team delivered strong financial results despite challenging macroeconomic conditions, resulting in full year adjusted EBITDA growth of 15% and adjusted EPS growth of 9% over full year 2022.”